© The Author 2006. Published by Oxford University Press.
ARTICLE |
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial
Affiliations of authors: Department of Surgery, Cardiff University, Cardiff, U.K. (REM, AG, IM, DC); Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, Falmer, U.K. (LF, AF); Department of Surgery, Royal Surrey County Hospital, Guildford, U.K. (MK); Department of Epidemiology, Statistics and Public Health, Cardiff University, Cardiff, U.K. (RGN); Department of Surgery, Western General Hospital, Edinburgh, U.K. (JMD, UC); Department of Surgery, Queen Alexandra Hospital, Portsmouth, U.K. (CY); Department of Surgery, Leeds General Infirmary, Leeds, U.K. (KH); Department of Surgery, South Manchester University Hospital, Manchester, U.K. (NB, LB); Department of Surgery, Queen Elizabeth Medical Centre, Birmingham, U.K. (DE); Department of Surgery, Derby City General Hospital, Derby, U.K. (MS); Department of Surgery, Edith Cavell Hospital, Peterborough, U.K. (TIA); Department of Surgery, Charing Cross Hospital, London, U.K. (DHS); Department of Nuclear Medicine, The Middlesex Hospital, London, U.K. (PJE)
Correspondence to: Robert E. Mansel, FRCS, Department of Surgery, Wales College of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom (e-mail: ManselRE{at}cf.ac.uk).
Background: Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes. We conducted a multicenter randomized trial to compare quality-of-life outcomes between patients with clinically node-negative invasive breast cancer who received sentinel lymph node biopsy and patients who received standard axillary treatment. Methods: The primary outcome measures were arm and shoulder morbidity and quality of life. From November 1999 to October 2003, 1031 patients were randomly assigned to undergo sentinel lymph node biopsy (n = 515) or standard axillary surgery (n = 516). Patients with sentinel lymph node metastases proceeded to delayed axillary clearance or received axillary radiotherapy (depending on the protocol at the treating institution). Intention-to-treat analyses of data at 1, 3, 6, and 12 months after surgery are presented. All statistical tests were two-sided. Results: The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively. Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P<.001), and axillary operative time was reduced (P = .055). Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P
.003). These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P>.05). Conclusion: Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Sentinel Lymph Node Biopsy in Early Breast Cancer: Has Its Time Come?
- Joseph Pater and Wendy Parulekar
J Natl Cancer Inst 2006 98: 568-569.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  N. C Turner and A. L Jones Management of breast cancer--Part I BMJ, July 4, 2008; 337(jul04_1): a421 - a421. [Full Text]
|
|
|
|
 |
|
 S. Samphao, J. M. Eremin, M. El-Sheemy, and O. Eremin Management of the Axilla in Women With Breast Cancer: Current Clinical Practice and a New Selective Targeted Approach Ann. Surg. Oncol., May 1, 2008; 15(5): 1282 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. ROCKSON and K. K. RIVERA Estimating the Population Burden of Lymphedema Ann. N.Y. Acad. Sci., May 1, 2008; 1131(1): 147 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Tan, D. Giri, A. J. Hummer, K. S. Panageas, E. Brogi, L. Norton, C. Hudis, P. I. Borgen, and H. S. Cody III Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up J. Clin. Oncol., April 10, 2008; 26(11): 1803 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. C. van der Ploeg, B. B. R. Kroon, N. Antonini, R. A. V. Olmos, E. J. T. Rutgers, and O. E. Nieweg Axillary and Extra-axillary Lymph Node Recurrences after a Tumor-Negative Sentinel Node Biopsy for Breast Cancer Using Intralesional Tracer Administration Ann. Surg. Oncol., April 1, 2008; 15(4): 1025 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G.J. Van der Zee, M. H. Oonk, J. A. De Hullu, A. C. Ansink, I. Vergote, R. H. Verheijen, A. Maggioni, K. N. Gaarenstroom, P. J. Baldwin, E. B. Van Dorst, et al. Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer J. Clin. Oncol., February 20, 2008; 26(6): 884 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J.T. Rutgers Sentinel Node Biopsy: Interpretation and Management of Patients With Immunohistochemistry-Positive Sentinel Nodes and Those With Micrometastases J. Clin. Oncol., February 10, 2008; 26(5): 698 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Somasundaram, D. W. Chicken, and M. R. S. Keshtgar Detection of the sentinel lymph node in breast cancer Br. Med. Bull., January 3, 2008; (2008) ldm032v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goyal, R. G. Newcombe, A. Chhabra, and R. E. Mansel Morbidity in Breast Cancer Patients with Sentinel Node Metastases Undergoing Delayed Axillary Lymph Node Dissection (ALND) Compared with Immediate ALND Ann. Surg. Oncol., January 1, 2008; 15(1): 262 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ponzone, P. Mininanni, E. Cassina, and P. Sismondi Axillary Reverse Mapping in Breast Cancer: Can we Spare what we Find? Ann. Surg. Oncol., January 1, 2008; 15(1): 390 - 391. [Full Text] [PDF]
|
|
|
|
 |
|
 J. MINIGH Sentinel Lymph Node Mapping of the Breast Radiol. Technol., January 1, 2008; 79(3): 243M - 257M. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Modi, A. W. B. Stanton, W. E. Svensson, A. M. Peters, P. S. Mortimer, and J. R. Levick Human lymphatic pumping measured in healthy and lymphoedematous arms by lymphatic congestion lymphoscintigraphy J. Physiol., August 15, 2007; 583(1): 271 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Thompson, S. Korourian, R. Henry-Tillman, L. Adkins, S. Mumford, K. C. Westbrook, and V S. Klimberg Axillary Reverse Mapping (ARM): A New Concept to Identify and Enhance Lymphatic Preservation Ann. Surg. Oncol., June 1, 2007; 14(6): 1890 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y A Masannat, A M Shaaban, V Speirs, G Coast, P Jackson, K Horgan, and A M Hanby Adverse effects of dyes used in sentinel node biopsy on immunocytochemical determination of hormone receptors in breast cancer cells J. Clin. Pathol., June 1, 2007; 60(6): 730 - 732. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sharma, W. Wang, J. C. Rasmussen, A. Joshi, J. P. Houston, K. E. Adams, A. Cameron, S. Ke, S. Kwon, M. E. Mawad, et al. Quantitative imaging of lymph function Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3109 - H3118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Blancas, J. Garcia-Puche, B Bermejo, E. Hanrahan, C Monteagudo, A Martinez-Agullo, R Rouzier, B. Hennessy, V Valero, and A Lluch Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor Ann. Onc., November 1, 2006; 17(11): 1644 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Sentinel-Node Biopsy vs. Axillary Dissection in Breast Cancer Journal Watch (General), May 23, 2006; 2006(523): 1 - 1. [Full Text]
|
|
|
|
 |
|
 J. Pater and W. Parulekar Sentinel lymph node biopsy in early breast cancer: has its time come? J Natl Cancer Inst, May 3, 2006; 98(9): 568 - 569. [Full Text] [PDF]
|
|